Explore
Validate
Learn
Western blot
ELISAAntibody data
- Antibody Data
- Antigen structure
- References [9]
- Comments [0]
- Validations
- Western blot [3]
- Immunohistochemistry [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ABIN151289 - Provider product page
- Provider
- antibodies-online
- Product name
- anti-Lysine (K)-Specific Demethylase 1A (KDM1A) antibody
- Antibody type
- Monoclonal
- Description
- Unpurified
- Reactivity
- Human, Mouse, Simian
- Host
- Mouse
- Isotype
- IgG
- Antibody clone number
- 1B2E5
- Vial size
- 0.1 mL
- Storage
- Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.
- Handling
- Avoid freeze-thaw cycles
Submitted references High immunoexpression of Ki67, EZH2, and SMYD3 in diagnostic prostate biopsies independently predicts outcome in patients with prostate cancer.
The KDM1A histone demethylase is a promising new target for the epigenetic therapy of medulloblastoma.
The lysine specific demethylase-1 (LSD1/KDM1A) regulates VEGF-A expression in prostate cancer.
Lysine-specific demethylase 1 (LSD1) and histone deacetylase 1 (HDAC1) synergistically repress proinflammatory cytokines and classical complement pathway components.
Lysine-specific demethylase 1 (LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug target in chondrosarcoma, Ewing's sarcoma, osteosarcoma, and rhabdomyosarcoma.
Elevated expression of LSD1 (Lysine-specific demethylase 1) during tumour progression from pre-invasive to invasive ductal carcinoma of the breast.
Lysine-specific demethylase 1 is highly expressed in solitary fibrous tumors, synovial sarcomas, rhabdomyosarcomas, desmoplastic small round cell tumors, and malignant peripheral nerve sheath tumors.
Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer.
Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology.
Lobo J, Rodrigues Â, Antunes L, Graça I, Ramalho-Carvalho J, Vieira FQ, Martins AT, Oliveira J, Jerónimo C, Henrique R
Urologic oncology 2018 Apr;36(4):161.e7-161.e17
Urologic oncology 2018 Apr;36(4):161.e7-161.e17
The KDM1A histone demethylase is a promising new target for the epigenetic therapy of medulloblastoma.
Pajtler KW, Weingarten C, Thor T, Künkele A, Heukamp LC, Büttner R, Suzuki T, Miyata N, Grotzer M, Rieb A, Sprüssel A, Eggert A, Schramm A, Schulte JH
Acta neuropathologica communications 2013 May 29;1:19
Acta neuropathologica communications 2013 May 29;1:19
The lysine specific demethylase-1 (LSD1/KDM1A) regulates VEGF-A expression in prostate cancer.
Kashyap V, Ahmad S, Nilsson EM, Helczynski L, Kenna S, Persson JL, Gudas LJ, Mongan NP
Molecular oncology 2013 Jun;7(3):555-66
Molecular oncology 2013 Jun;7(3):555-66
Lysine-specific demethylase 1 (LSD1) and histone deacetylase 1 (HDAC1) synergistically repress proinflammatory cytokines and classical complement pathway components.
Janzer A, Lim S, Fronhoffs F, Niazy N, Buettner R, Kirfel J
Biochemical and biophysical research communications 2012 May 18;421(4):665-70
Biochemical and biophysical research communications 2012 May 18;421(4):665-70
Lysine-specific demethylase 1 (LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug target in chondrosarcoma, Ewing's sarcoma, osteosarcoma, and rhabdomyosarcoma.
Bennani-Baiti IM, Machado I, Llombart-Bosch A, Kovar H
Human pathology 2012 Aug;43(8):1300-7
Human pathology 2012 Aug;43(8):1300-7
Elevated expression of LSD1 (Lysine-specific demethylase 1) during tumour progression from pre-invasive to invasive ductal carcinoma of the breast.
Serce N, Gnatzy A, Steiner S, Lorenzen H, Kirfel J, Buettner R
BMC clinical pathology 2012 Aug 24;12:13
BMC clinical pathology 2012 Aug 24;12:13
Lysine-specific demethylase 1 is highly expressed in solitary fibrous tumors, synovial sarcomas, rhabdomyosarcomas, desmoplastic small round cell tumors, and malignant peripheral nerve sheath tumors.
Schildhaus HU, Riegel R, Hartmann W, Steiner S, Wardelmann E, Merkelbach-Bruse S, Tanaka S, Sonobe H, Schüle R, Buettner R, Kirfel J
Human pathology 2011 Nov;42(11):1667-75
Human pathology 2011 Nov;42(11):1667-75
Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer.
Kauffman EC, Robinson BD, Downes MJ, Powell LG, Lee MM, Scherr DS, Gudas LJ, Mongan NP
Molecular carcinogenesis 2011 Dec;50(12):931-44
Molecular carcinogenesis 2011 Dec;50(12):931-44
Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology.
Lim S, Janzer A, Becker A, Zimmer A, Schüle R, Buettner R, Kirfel J
Carcinogenesis 2010 Mar;31(3):512-20
Carcinogenesis 2010 Mar;31(3):512-20
No comments: Submit comment
Supportive validation
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- WB
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- WB
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- WB
Supportive validation
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- IHC
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- IHC
